HK1176075A1 - 抗體可變區的糖基化 - Google Patents

抗體可變區的糖基化

Info

Publication number
HK1176075A1
HK1176075A1 HK13103092.6A HK13103092A HK1176075A1 HK 1176075 A1 HK1176075 A1 HK 1176075A1 HK 13103092 A HK13103092 A HK 13103092A HK 1176075 A1 HK1176075 A1 HK 1176075A1
Authority
HK
Hong Kong
Prior art keywords
variable region
antibody glycosylation
glycosylation
antibody
variable
Prior art date
Application number
HK13103092.6A
Other languages
English (en)
Inventor
．洛茨西爾
．赫伯
．舒鮑爾
．魏爾
．布洛克豪斯
．寶曼
．科爾
．紹布瑪
．蘭奇
Original Assignee
豪夫邁‧羅氏有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 豪夫邁‧羅氏有限公司 filed Critical 豪夫邁‧羅氏有限公司
Publication of HK1176075A1 publication Critical patent/HK1176075A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
HK13103092.6A 2005-12-12 2009-07-17 抗體可變區的糖基化 HK1176075A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05027090 2005-12-12

Publications (1)

Publication Number Publication Date
HK1176075A1 true HK1176075A1 (zh) 2013-07-19

Family

ID=37745986

Family Applications (2)

Application Number Title Priority Date Filing Date
HK09106521.6A HK1130066A1 (en) 2005-12-12 2009-07-17 Antibody glycosylation in the variable region
HK13103092.6A HK1176075A1 (zh) 2005-12-12 2009-07-17 抗體可變區的糖基化

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK09106521.6A HK1130066A1 (en) 2005-12-12 2009-07-17 Antibody glycosylation in the variable region

Country Status (34)

Country Link
US (2) US8906370B2 (zh)
EP (2) EP2377886A1 (zh)
JP (1) JP5145241B2 (zh)
KR (2) KR101401159B1 (zh)
CN (2) CN102659943B (zh)
AR (1) AR057233A1 (zh)
AT (1) ATE517923T1 (zh)
AU (1) AU2006326301B2 (zh)
BR (1) BRPI0619605B8 (zh)
CA (1) CA2632828C (zh)
CR (1) CR10000A (zh)
CY (1) CY1114783T1 (zh)
DK (1) DK1960428T3 (zh)
DO (1) DOP2006000278A (zh)
EC (1) ECSP088524A (zh)
ES (1) ES2368591T3 (zh)
HK (2) HK1130066A1 (zh)
IL (1) IL191004A (zh)
JO (1) JO2824B1 (zh)
MA (1) MA30038B1 (zh)
MY (1) MY155286A (zh)
NO (1) NO346105B1 (zh)
NZ (1) NZ568241A (zh)
PE (3) PE20100748A1 (zh)
PL (1) PL1960428T3 (zh)
PT (1) PT1960428E (zh)
RS (1) RS52004B (zh)
RU (1) RU2438706C2 (zh)
SI (1) SI1960428T1 (zh)
TW (1) TWI382990B (zh)
UA (1) UA99097C2 (zh)
UY (1) UY30003A1 (zh)
WO (1) WO2007068429A1 (zh)
ZA (1) ZA200805038B (zh)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
PT1954718E (pt) 2005-11-30 2014-12-16 Abbvie Inc Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos
NZ568241A (en) * 2005-12-12 2011-08-26 Hoffmann La Roche Antibodies against amyloid beta 4 with glycosylation in the variable region
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
MX2009006199A (es) * 2006-12-11 2009-06-22 Hoffmann La Roche Formulacion parenteral de anticuerpos abeta.
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
KR101163295B1 (ko) * 2007-06-29 2012-07-05 에프. 호프만-라 로슈 아게 향상된 면역글로불린을 생산하는 중쇄 돌연변이체
ES2473623T3 (es) * 2007-08-20 2014-07-07 Glaxo Group Limited Procedimiento de producción
AU2008311367B2 (en) 2007-10-05 2014-11-13 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
CN101896163A (zh) * 2007-12-21 2010-11-24 弗·哈夫曼-拉罗切有限公司 抗体制剂
CA2975228C (en) * 2008-05-02 2020-07-21 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
US20120282654A1 (en) * 2009-04-29 2012-11-08 Schering Corporation Antibody purification
US20130116413A1 (en) * 2009-12-29 2013-05-09 Dr. Reddy's Laboratories, Inc. Purification of proteins
CN102781962B (zh) 2010-03-03 2014-12-10 阿布林克斯公司 双互补位A-β结合多肽
MX360403B (es) 2010-04-15 2018-10-31 Abbvie Inc Proteinas de union a amiloide beta.
CN103179981B (zh) 2010-07-30 2017-02-08 Ac免疫有限公司 安全和功能性的人源化抗β‑淀粉样蛋白抗体
EP2603524A1 (en) 2010-08-14 2013-06-19 AbbVie Inc. Amyloid-beta binding proteins
WO2012142301A2 (en) 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
IN2014CN03555A (zh) 2011-10-25 2015-07-03 Onclave Therapeutics Ltd
WO2013081946A1 (en) * 2011-12-02 2013-06-06 Plaxgen, Inc. Plaque array method and compositions for forming and detecting plaques
RU2014140137A (ru) 2012-03-08 2016-04-27 Ф.Хоффманн-Ля Рош Аг Лекарственный препарат антитела к бета-амилоиду
TR201909156T4 (tr) * 2012-08-29 2019-07-22 Hoffmann La Roche Kan beyin bariyeri mekiği.
CN102998454A (zh) * 2012-12-11 2013-03-27 华中师范大学 一种检测生物体内邻苯二甲酸二丁酯相对含量的方法
US9587022B2 (en) 2012-12-18 2017-03-07 The Rockefeller University Glycan-modified anti-CD4 antibody with improved HIV-1 neutralizing activity
EP2934589B1 (en) * 2012-12-18 2021-01-13 The Rockefeller University Glycan-modified anti-cd4 antibodies for hiv prevention and therapy
BR112015019341A2 (pt) 2013-02-13 2017-08-22 Lab Francais Du Fractionnement Anticorpo anti-tnf-alfa, composição que compreende o anticorpo, método para produzir uma população de anticorpos, células epiteliais da glândula mamária, mamífero não humano transgênico, e, composição de anticorpo anti-tnf monoclonal
JP6169885B2 (ja) 2013-05-07 2017-07-26 株式会社日立製作所 精製装置及び精製方法
NZ756750A (en) 2013-09-13 2022-05-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
ES2915378T3 (es) 2013-09-13 2022-06-22 Hoffmann La Roche Procedimientos para detectar y cuantificar una proteína de célula huésped en líneas celulares
CA2931056C (en) 2013-11-22 2023-02-28 The University Of Tokyo Carrier for use in delivering drug, conjugate, composition comprising same, and method for administrating same
CA2944402A1 (en) 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
HUE057952T2 (hu) 2015-06-24 2022-06-28 Hoffmann La Roche Anti-transzferrin receptor antitestek testreszabott affinitással
CN116063375A (zh) * 2015-08-21 2023-05-05 豪夫迈·罗氏有限公司 在亲和层析中减少宿主细胞蛋白的方法
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
JP6657392B2 (ja) 2015-10-02 2020-03-04 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗ヒトｃｄ２０／ヒトトランスフェリン受容体抗体及び使用方法
EP3155958B1 (en) * 2015-10-16 2021-11-17 Roche Diabetes Care GmbH A method for operating a system and a system
KR20180088828A (ko) 2015-11-09 2018-08-07 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타에서의 n-말단 에피토프 및 이에 형태적으로-선택적인 항체
US10774120B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
US10759837B2 (en) 2015-11-09 2020-09-01 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
US10792477B2 (en) * 2016-02-08 2020-10-06 Orbusneich Medical Pte. Ltd. Drug eluting balloon
EP3427183A1 (en) * 2016-03-10 2019-01-16 Genomic Vision Method of curvilinear signal detection and analysis and associated platform
EP3448874A4 (en) * 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
TWI798751B (zh) 2016-07-01 2023-04-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
CA3031135A1 (en) 2016-07-18 2018-01-25 The University Of British Columbia Antibodies to amyloid beta
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
JPWO2018221244A1 (ja) * 2017-05-30 2019-11-21 森永乳業株式会社 脳機能改善用組成物
WO2019014768A1 (en) 2017-07-18 2019-01-24 The University Of British Columbia ANTI-BETA-AMYLOID ANTIBODY
CN108048477A (zh) * 2017-12-15 2018-05-18 南京理工大学 基于大肠杆菌表达系统的制备多肽的方法
EP3778875A1 (en) 2019-08-14 2021-02-17 MaxiVax SA Immortalized myoblast cell lines and uses thereof
EP4185612A1 (en) 2020-07-23 2023-05-31 Othair Prothena Limited Anti-abeta antibodies
MX2023005581A (es) 2020-11-16 2023-05-29 Hoffmann La Roche Glucoformas de fab ricas en manosa.
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
CN114591429B (zh) * 2022-05-07 2022-08-09 北京第一生物化学药业有限公司 结合β-淀粉样蛋白的抗体及其用途
WO2024157085A1 (en) 2023-01-26 2024-08-02 Othair Prothena Limited Methods of treating neurological disorders with anti-abeta antibodies
CN117783359A (zh) * 2023-12-28 2024-03-29 中国计量科学研究院 一种基于串联质谱的转基因蛋白多靶同检方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5811310A (en) 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
CA1339014C (en) 1987-10-08 1997-03-25 Ronald E. Majocha Antibodies to a4 amyloid peptide
JP2780507B2 (ja) 1991-03-29 1998-07-30 松下電器産業株式会社 内燃機関用フィルタ再生装置
US5955317A (en) 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
US5750349A (en) 1993-01-25 1998-05-12 Takeda Chemical Industries Ltd. Antibodies to β-amyloids or their derivatives and use thereof
US5443953A (en) * 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
GB9416007D0 (en) * 1994-08-08 1994-09-28 Erba Carlo Spa Anthracyclinone derivatives
US5688651A (en) 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
AU5976996A (en) * 1995-06-06 1996-12-24 Stemcell Therapeutics L.L.C. Glycoprotein gp105 on bl3 hematopoietic stem cells
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
PT1161449E (pt) * 1999-03-04 2007-10-12 Praecis Pharm Inc Moduladores de agregação do péptido beta-amilóide compreendendo d-aminoácidos
DK1409654T3 (da) 1999-06-16 2008-12-08 Boston Biomedical Res Inst Immunologisk styring af beta-amyloid-niveauer in vivo
EP1209969A2 (en) 1999-08-31 2002-06-05 RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. Peptides and substances, methods and devices using same for diagnosing and treating neurodegenerative disorders
US20020094335A1 (en) 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
AU784312B2 (en) 1999-11-29 2006-03-09 Bellus Health (International) Limited Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
EP1125905A1 (en) 2000-02-16 2001-08-22 Pepscan Systems B.V. Segment synthesis
SK288711B6 (sk) 2000-02-24 2019-11-05 Univ Washington Humanizovaná protilátka, jej fragment a ich použitie, polynukleová kyselina, expresný vektor, bunka a farmaceutický prostriedok
CA2313828A1 (en) 2000-08-01 2002-02-01 Institut De Recherches Cliniques De Montreal/Ircm Post-translational processing of .beta.-secretase (bace): the pro-and transmembrane/cytosolic domains affect its cellular activity and amyloid a.beta. production
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
WO2002064734A2 (en) 2000-12-19 2002-08-22 Palatin Technologies, Inc. Identification of target-specific folding sites in peptides and proteins
DE60230736D1 (de) 2001-04-30 2009-02-26 Lilly Co Eli HUMANISIERTE ANTIKÖRPER DIE DAS BETA-AMYLOID PEPTID ERKENNEN& x9;
DE60229051D1 (de) 2001-04-30 2008-11-06 Lilly Co Eli Humanisierte antikörper
EP1944040B1 (en) * 2001-08-17 2012-08-01 Washington University Assay method for Alzheimer's disease
WO2003016466A2 (en) 2001-08-17 2003-02-27 Eli Lilly And Company ANTI-Aβ ANTIBODIES
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
BR0315157A (pt) 2002-10-09 2005-08-09 Rinat Neuroscience Corp Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
NZ568241A (en) * 2005-12-12 2011-08-26 Hoffmann La Roche Antibodies against amyloid beta 4 with glycosylation in the variable region
MX2009006199A (es) * 2006-12-11 2009-06-22 Hoffmann La Roche Formulacion parenteral de anticuerpos abeta.

Also Published As

Publication number Publication date
CY1114783T1 (el) 2016-12-14
ZA200805038B (en) 2009-06-24
JP2009520691A (ja) 2009-05-28
PE20071002A1 (es) 2007-11-19
HK1130066A1 (en) 2009-12-18
MY155286A (en) 2015-09-30
AR057233A1 (es) 2007-11-21
CN101351476B (zh) 2013-04-03
AU2006326301A1 (en) 2007-06-21
RU2438706C2 (ru) 2012-01-10
KR101401159B1 (ko) 2014-05-29
ES2368591T3 (es) 2011-11-18
UY30003A1 (es) 2007-08-31
PT1960428E (pt) 2011-10-07
SI1960428T1 (sl) 2011-10-28
UA99097C2 (ru) 2012-07-25
AU2006326301B2 (en) 2011-04-21
CN102659943A (zh) 2012-09-12
ECSP088524A (es) 2008-07-30
CR10000A (es) 2008-07-29
NZ568241A (en) 2011-08-26
EP1960428B1 (en) 2011-07-27
US9272031B2 (en) 2016-03-01
CA2632828C (en) 2012-07-10
BRPI0619605B1 (pt) 2019-08-13
RS52004B (en) 2012-04-30
KR20080077132A (ko) 2008-08-21
JO2824B1 (en) 2014-09-15
EP1960428A1 (en) 2008-08-27
IL191004A (en) 2013-08-29
WO2007068429A1 (en) 2007-06-21
JP5145241B2 (ja) 2013-02-13
US20150165022A1 (en) 2015-06-18
US8906370B2 (en) 2014-12-09
BRPI0619605A8 (pt) 2019-01-15
CA2632828A1 (en) 2007-06-21
MA30038B1 (fr) 2008-12-01
EP2377886A1 (en) 2011-10-19
RU2008128138A (ru) 2010-01-20
PE20100748A1 (es) 2010-11-12
DOP2006000278A (es) 2007-07-15
PL1960428T3 (pl) 2012-02-29
US20090252724A1 (en) 2009-10-08
TWI382990B (zh) 2013-01-21
BRPI0619605B8 (pt) 2021-05-25
TW200736273A (en) 2007-10-01
CN101351476A (zh) 2009-01-21
CN102659943B (zh) 2015-07-01
NO346105B1 (no) 2022-02-21
KR20120089483A (ko) 2012-08-10
PE20100684A1 (es) 2010-10-04
ATE517923T1 (de) 2011-08-15
BRPI0619605A2 (pt) 2011-10-11
DK1960428T3 (da) 2011-08-22
NO20082874L (no) 2008-08-28

Similar Documents

Publication Publication Date Title
HK1130066A1 (en) Antibody glycosylation in the variable region
HK1218126A1 (zh) 抗體
IL187106A (en) Sclerostin binds antibody
IL190472A0 (en) Anti-glypican-3 antibody
IL185366A0 (en) Antibody
IL187316A0 (en) Anti-interleukin 2 antibodies
IL186500A0 (en) Protein glycosylation
GB0502992D0 (en) The ballcaster
GB0523899D0 (en) The one
GB0511610D0 (en) The motor-roll-off
PL376079A1 (pl) Piec akumulacyjny obiektu
GB0516424D0 (en) Improvement in the lamp
GB0526162D0 (en) The gift
GB0500400D0 (en) Antibody
GB0502412D0 (en) The sproke
GB0506202D0 (en) The uni-tray
GB0511228D0 (en) The cat-lock
GB0500175D0 (en) The astrocelesphere
GB0517209D0 (en) The wayfinder
GB0519318D0 (en) The wheelbox
GB0521054D0 (en) The chew-it-bar
GB0521243D0 (en) The grapler
GB0524595D0 (en) The guillospade
GB0524920D0 (en) The clipstrip